BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37937321)

  • 21. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
    Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
    Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
    Mansour MSI; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
    Cancer Cytopathol; 2017 Dec; 125(12):908-917. PubMed ID: 28922567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study.
    Ghasemi D; Ameli F; Nili F; Edjtemaei R; Sheikhhasani S
    BMC Cancer; 2022 Dec; 22(1):1362. PubMed ID: 36581850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of DNA mismatch repair proteins in prostate cancer.
    Sharma M; Yang Z; Miyamoto H
    Medicine (Baltimore); 2020 May; 99(19):e20124. PubMed ID: 32384491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer.
    Liu H; Sun L; Lian J; Wang L; Xi Y; Zhao G; Wang J; Lan X; Du H; Yan W; Bu P; Wang P; Moore A; Zhao H
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11397-11410. PubMed ID: 37378674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.
    Hongo T; Yamamoto H; Jiromaru R; Yasumatsu R; Kuga R; Nozaki Y; Hashimoto K; Matsuo M; Wakasaki T; Tamae A; Taguchi K; Toh S; Masuda M; Nakagawa T; Oda Y
    Mod Pathol; 2021 Nov; 34(11):1966-1978. PubMed ID: 34218257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
    Filippov-Levy N; Cohen-Schussheim H; Tropé CG; Hetland Falkenthal TE; Smith Y; Davidson B; Reich R
    Gynecol Oncol; 2018 Mar; 148(3):559-566. PubMed ID: 29310950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant pleural effusion cell blocks are reliable resources for PD-L1 analysis in advanced lung adenocarcinomas: a concordance study with matched histologic samples.
    Mahajan S; Nambirajan A; Gupta I; Gupta N; Gupta P; Jain D
    J Am Soc Cytopathol; 2022; 11(5):253-263. PubMed ID: 35589508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
    Gottlieb CE; Mills AM; Cross JV; Ring KL
    Gynecol Oncol; 2017 Mar; 144(3):607-612. PubMed ID: 28065619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.
    Masadah R; Ikram D; Riadi R; Tangdiung Y; Nelwan BJ; Ghaznawie M; Rauf S; Faruk M
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):249-255. PubMed ID: 38285791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
    Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R
    Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PTEN Deficiency in Tubo-Ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
    Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
    Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
    Davidson B
    Hum Pathol; 2016 Dec; 58():123-127. PubMed ID: 27589896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
    Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
    Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
    Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
    BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
    Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
    Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
    Sherman-Samis M; Onallah H; Holth A; Reich R; Davidson B
    Gynecol Oncol; 2019 Jun; 153(3):651-660. PubMed ID: 30904337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.